R
ecent studies have raised concerns about the reliability of four compendia currently used by Medicare and other payers to help determine which cancer drugs will be covered for which offlabel indications. Now, experts are looking for ways to improve the compendia, even as oncologists debate their usefulness to guide treatment decisions.
The studies, a series of reports funded by the Centers for Medicare and Medicaid Services (CMS) and conducted by the Agency for Healthcare Research and Quality (AHRQ), have found that the current compendia lack transparency, cite little current evidence, lack systematic methods to review and update evidence, and are replete with confl ictof-interest issues.
The findings would seem to matter. Up to 75% of all uses of cancer therapies are off label, according to a 2005 estimate by the National Comprehensive Cancer Network (NCCN), whose own compendium was later chosen for use by CMS. Louis B. Jacques, M.D., who directs the division of items and devices coverage and analysis group at CMS, emphasizes that compendia -essentially lists of drugs for certain indications -are not a shorthand for coverage. Nevertheless, reimbursement issues were at least partly behind CMS's decision last year to add more compendia to the one then in use for Medicare decisions ( see sidebar).
The fi rst AHRQ report, in 2006, compared six compendia for 14 off-label indications; examples include bevacizumab and oxaliplatin for breast and lung cancers, as well as docetaxel for esophageal, gastric, and ovarian cancers. Led by Amy Abernethy, M.D. , a medical oncologist at Duke University Medical Center in Durham, N.C., the researchers compared 1,500 citations of evidence in the compendia with their own systematic analysis of the scientifi c literature. The second report, published in March in the Annals of Internal Medicine , added another 25 reports to the analysis of one indication, gemcitabine for bladder cancer, to see whether the compendia had improved.
Both analyses found that the compendia varied substantially in whether they listed any given agent and cancer combination and that they cited different literature for the same indication. The researchers found that DRUGDEX listed the most off-label indications and that AHFS DI , published by the American Hospital Formulary Service (AHFS), listed the fewest. The two other compendia were in the middle.
Not Up to Date
Abernethy said there was little agreement between the results of the team's own systematic reviews and the evidence cited in the compendia, that the evidence cited was scanty and inconsistent across compendia, and that it was neither the most recent evidence nor the highest available level of evidence.
For gemcitabine for bladder cancer, for instance, the researchers identifi ed 43 published phase I -III studies and 15 conference abstracts. The compendia, in contrast, referred to between zero and seven, Abernethy said. The 2008 review identifi ed an additional 25 reports published in 2006 and 2007, but only one compendium increased its number of citations, adding three; the others had little or no change. "We were looking at whether the compendia do what they say they are going to do, which is to be a synthesized evidence resource to assist with off-label prescribing. And in fact they don't do a very good job of that," Abernethy said. Although the compendia lack transparency, and lack systematic methods to review or update evidence, "the biggest problem is that they are not keeping up with the literature," she said. "It is a monstrous task. The evidence moves so fast and the information is so hard to synthesize."
Abernethy's newest study is a systematic review of the literature for 17 drug -disease combinations compared to current compendia, submitted to AHRQ in September. "We did this three times because no matter what we did we were always out of date and couldn't keep up, she said. "We need to come up with a real-time way to do this."
Bill McGivney, Ph.D., chief executive of the NCCN, strongly disagreed that NCCN's compendium is out of date. "To say that is ludicrous," he says. The compendium is derived from information in the NCCN Guidelines , and both "are updated sometimes within days of a study being presented or published in the literature."
Conflicts of Interest
AHRQ has also begun to focus on confl icts of interest, another major, and now high-visibility, issue for compendia producers. It's not hard to see how confl icts of interest occur, said Ross McKinney, M.D. , a Duke pediatrician who is chief author of a white paper on the subject, dated April 27 and posted on the agency's Web site. Manufacturers have a direct 
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ment for the Healthcare and Science business of Thomson Reuters, which publishes DRUGDEX , said, "our confl ict-of-interest policy is consistent with industry standards" and that "Thomson Reuters is committed to providing unbiased, reliable, and evidence-based information products and services, and we believe DRUGDEX refl ects this commitment."
Clinical Pharmacology is the only compendium that uses a review process that is almost entirely in-house, and corporate policies prohibit staff members from having fi nancial relations with industry. McKinney said that although this is the "purest" approach and best option to limit confl icts, Gold Standard, which publishes Clinical Pharmacology , was purchased by Reed Elsevier, a large Dutch publishing and information services conglomerate that owns a business services component. This purchase "creates risk for confl ict of interest."
That isn't the case, said Karl Matuszewski, Pharm.D., an editor in chief who is responsible for the clinical content of Clinical Pharmacology . "We have very specifi c restrictions," he said.
A Practice Tool?
Along with the confl ict-of-interest and other issues in the compendia, the question interest in maximizing the number of accepted indications that are listed in approved compendia, which would then be eligible for payment, whereas insurance companies have an interest in limiting the number of those accepted indications. Furthermore, compendium writers are often practicing physicians who want to have more treatment options available to them in which to treat their patients, McKinney said.
CMS's Jacques sees even more potential confl icts of interest that could infl uence compendium writers "from the time that people decide what kinds of clinical trials to do, to the publication or the suppression of the results of clinical trials, to the bona fi de or biased way in which those published results might be interpreted by people, to even a physician's decision to use one drug or to recommend one strategy versus another."
Because of the potential for confl icts of interest, Congress included a provision in the 2008 Medicare Improvements for Patients and Providers Act that explicitly prohibits inclusion of compendia that do not have a publicly transparent process for evaluating therapies and identifying potential confl icts of interest.
AHRQ found that the four compendia used by CMS face the risk of confl icts ranging from potential corporate or institutional confl icts of interest ( AHFS DI , DRUGDEX , and Clinical Pharmacology ) to the diffi culty of recruiting physicians to help draft compendia who do not have their own confl ict of interest ( NCCN Drugs & Biologics Compendium ).
"Almost nobody was completely free from the potential of confl ict of interest," McKinney said. But he added that all the compendium developers are aware of the issue and some have instituted policies intended to control and minimize the confl icts. By January 2010, for instance, NCCN will post online the amount of money associated with specifi c relationships that its 834 expert panelists have with pharmaceutical and insurance companies, according to McGivney. McKinney said that AHFS DI will now no longer require a $50,000 application fee to drug companies who seek an expedited review of a new off-label indication. AHRQ had cited this arrangement as a potential confl ict of interest. However, AHFS strongly contests this point. The program was stopped not because of the white paper but because applications had "dried up as a result of a change in the compendial landscape [i.e., addition of three new compendia]," according to Gerald McEvoy at AHFS. "We had very strong fi rewalls in place to avoid potential confl icts," he wrote in an e-mail. "The record simply does not support the hypothesis of the white paper authors about potential pressures for positive evaluations since less than a third of our determinations using this process were positive."
The other two compendia also stand fi rmly by the integrity of their product. McKinney cited DRUGDEX as having the highest cutoff point ($100,000) for disclosure of potential fi nancial confl icts beyond which external reviewers who contribute to the compendia may not participate in evaluation of evidence. "The public could reasonably wonder if someone receiving slightly less than $100,000 per year might be biased," McKinney said in the report. The high fi gure accounted for the relatively few confl icted individuals listed on DRUGDEX ' s Web site, he added. But Jill Sutton, vice president of product manage-
Compendia: A Primer
A compendium is a comprehensive listing of drugs and biologicals that includes a summary of the dosing and characteristics of the drug and recommended uses for specific diseases.
But compendia have morphed into other uses, such as to aid reimbursement decisions. In the 1980s, payment for growing off-label cancer therapy deemed to be "experimental," such as laetrile and shark cartilage, became an issue. So in 1993, Congress directed the Medicare program to refer to three existing published compendia, American Medical Association Drug Evaluations ( AMA-DE ), United States Pharmacopoeia Drug Information ( USP DI ), and American Hospital Formulary Service Drug Information ( AHFS DI ), to identify off-label but medically accepted uses of drugs and biologicals in cancer chemotherapy regimens.
Although the statute was specific to reimbursement by CMS, most other insurance payers and state legislatures followed the same criteria. The compendia essentially functioned as gatekeepers for off-label prescribing in oncology.
But the list of approved compendia shifted. AMA-DE and USP DI were discontinued. In response to concerns about the influence of the remaining single recognized compendium, CMS in 2007 established a process to revise the list.
Current CMS-approved compendia include the following:
• Others have much more positive views of compendia. McKinney said that even with their undeniable inconsistencies and shortcomings, they effectively get information out to practicing physicians "who use that information to undergird clinical decisions."
But he added that a survey is needed to fi nd out how they actually use them.
Duke's Abernethy said that she is a fan of compendia even as she uncovers their substantial fl aws. She said the fact that four compendia exist, as opposed to one in 2007, offers her a broader "bandwidth" by which to capture benefi cial information.
"In my mind, even though I think the compendia are a pretty unreliable resource, increasing the number of compendia is a very patient-centered strategy," she said. It increases the chance that one of them will capture promising treatment information that will result in reimbursement of an off-label cancer therapy. "I have my own confl ict of interest, because as a physician, I need to take care of the patient sitting in front of me," she said.
But the CMS's Jacques argues that the potential for confl icts of interest in compendia and beyond can result in patients being at the mercy of the system. "It's a hard time to be a patient," he said. "It's a hard time even to be an educated patient."
